Equities

Medlive Technology Co Ltd

Medlive Technology Co Ltd

Actions
Health CareHealth Care Providers
  • Price (HKD)8.95
  • Today's Change0.17 / 1.94%
  • Shares traded817.00k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of May 20 2022 09:08 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Medlive Technology Co Ltd is a China-based investment holding company mainly operates online professional physician platform. The Company mainly operates three segments. Its Precision Marketing and Corporate Solutions segment provides precision marketing solutions and corporate solutions. Its precision marketing solutions include digital detailing, digital marketing consulting and digital content creation services. Its revenue of its corporate solutions is primarily software as a service (SaaS). The Medical Knowledge Solutions segment mainly provides professional medical information and medical software services. The Intelligent Patient Management Solutions segment mainly provides online patient consultation and prescription services and patient management services. The Company mainly conducts its business within domestic market.

  • Revenue in HKD (TTM)330.56m
  • Net income in HKD47.20m
  • Incorporated2013
  • Employees502.00
  • Location
    Medlive Technology Co LtdUgland HousePO Box 309BEIJING KY1-1104ChinaCHN
  • Websitehttp://www.medlive.cn
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Powerlong Commercial Management Hlgs Ltd2.86bn509.19m4.01bn6.89k7.801.407.771.400.79880.79884.494.440.5137--17.67415,845.309.157.5514.6515.0733.3529.6417.8013.90----0.239344.6128.2526.7743.6247.4231.03--
Antengene Corporation Ltd33.43m-761.82m4.52bn329.00--1.57--135.33-1.22-1.220.05354.350.01--1.14101,622.00-22.79---24.09--84.08---2,278.60--15.12-9.880.0062------77.62------
Clover Biopharmaceuticals Ltd-100.00bn-100.00bn4.66bn814.00-----------------------------------------------------559.03------
MicroPort CardioFlow Medtech Corp233.37m-212.98m5.22bn451.00--1.45--22.37-0.0908-0.09080.10011.50------517,456.80--------1.14---91.26--15.31--0.039--93.21--53.96------
Zall Smart Commerce Group Ltd121.50bn-1.54bn5.94bn1.83k--0.2958--0.0489-0.1309-0.130910.321.621.7213.4817.2166,577,500.00-2.390.3309-5.400.64950.84721.80-1.390.27040.7691-0.38180.51380.0043.68143.82-5.27--43.40--
Jacobio Pharmaceuticals Group Co Ltd177.59m-350.02m6.00bn262.00--3.15--33.80-0.4683-0.46830.23762.470.0852--1.29677,807.60-16.78---17.54--8.40---197.10------0.0041---68.58--80.10------
Natural Dairy (NZ) Holdings Ltd14.10m-764.06m6.03bn211.00------427.50-0.2821-0.28210.00520.2640.0052.700.3147---27.04-15.31-50.65-17.4956.9027.98-5,418.45-638.791.11-0.18830.2746---54.78---1,057.95------
Brii Biosciences Ltd0.00-4.84bn6.26bn113.00--1.61-----13.04-13.040.005.39------0.00--------------------0.0065-------250.02------
Medlive Technology Co Ltd330.56m47.20m6.27bn502.00117.081.36104.9218.960.0750.0750.51996.43------658,484.80--------70.57--15.91--35.45--0.0033--33.21---52.33------
Alphamab Oncology169.70m-479.29m6.59bn459.00--3.03--38.86-0.5124-0.51240.18142.320.05460.05921.92369,710.20-15.43---18.84--97.93---282.44--3.23-25.120.2541------3.59------
Tongdao Liepin Group3.08bn156.22m7.08bn5.79k44.442.04--2.300.30420.30425.986.620.568--28.50532,281.804.102.636.313.8977.9678.827.225.21--14.290.0440.0041.8135.19150.67--10.89--
Shoucheng Holdings Ltd1.20bn-1.10bn8.23bn512.00--0.8125--6.89-0.1506-0.15060.16571.390.0869--7.342,334,045.00-8.100.6359-8.710.687945.7916.56-93.185.29----0.1863699.8769.302.91-266.31---28.23--
Data as of May 20 2022. Currency figures normalised to Medlive Technology Co Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

15.98%Per cent of shares held by top holders
HolderShares% Held
FIL Investment Management (Hong Kong) Ltd.as of 04 Mar 202230.38m4.26%
Fidelity Management & Research Co. LLCas of 08 Feb 202222.34m3.13%
Capital Research & Management Co. (World Investors)as of 31 Mar 202212.91m1.81%
GIC Pte Ltd. (Investment Management)as of 14 Jul 202111.42m1.60%
FIL Investment Management (Singapore) Ltd.as of 04 Mar 20228.61m1.21%
Fidelity Management & Research (Hong Kong) Ltd.as of 08 Feb 20228.19m1.15%
Springhill Fund Asset Management (HK) Co. Ltd.as of 14 Jul 20215.71m0.80%
Matthews International Capital Management LLCas of 14 Jul 20215.71m0.80%
The Vanguard Group, Inc.as of 31 Mar 20225.32m0.75%
Columbia Management Investment Advisers LLCas of 31 Dec 20213.50m0.49%
More ▼
Data from 15 Nov 2021 - 10 May 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.